Navigation Links
Pain Management Therapeutics Market to 2017 - Price Competition to Intensify Following Patent Expiries of Lyrica and Cymbalta
Date:11/28/2011

22

3.4 Revenue 23

3.5 Major Marketed Pain Management Drugs 24

3.5.1 Lyrica (pregabalin) 25

3.5.2 Cymbalta (duloxetine) 26

3.5.3 Celebrex (celecoxib) 26

3.5.4 Voltaren Gel (diclofenac sodium) 27

3.5.5 Imitrex(sumatriptan succinate) 27

3.5.6 Savella (milnacipran hydrochloride) 28

3.5.7 Lidoderm (lidocaine patch) 28

3.5.8 Qutenza (capsaicin) 28

3.5.9 Zomig (zolmitriptan) 29

3.5.10 Maxalt (rizatriptan benzoate) 29

3.6 Annual Cost of Therapy 30

3.7 Treatment Usage Patterns 31

3.7.1 Diseased Population 33

3.7.2 Treatment Seeking Population 34

3.7.3 Diagnosed Population 35

3.7.4 Prescription Population 36

3.8 Drivers and Restraints of the Pain Management Therapeutics Market 37

3.8.1 Drivers 37

3.8.2 Restraints 38

4 Pain Management Therapeutics Market - Therapeutic Landscape 39

4.1 Pain Management Therapeutics Market for Fibromyalgia 39

4.1.1 Introduction 39

4.1.2 Revenue 40

4.1.3 Branded vs. Generic Share 41

4.1.4 Annual Cost of Therapy 42

4.1.5 Treatment Flow Algorithm 43

4.1.6 Treatment Usage Patterns 44

4.1.7 Geographical Segmentation 50

4.1.8 Drivers and Restraints for the Fibromyalgia Market 53

4.1.9 Restraints for the Fibromyalgia Pain Relief Market 54

4.2 Pain Management Therapeutics for Neuropathic Pain 54

4.2.1 Introduction 54

4.2.2 Revenue 55

4.2.3 Branded Vs Generic Share 56

4.2.4 Annual Cost of Therapy 57

4.2.5 Treatment Flow Algorithm 58

4.2.6 Treatment Usage Patterns 59

4.2.7 Geographical Segmentation 64

4.2.8 Drivers and Restraints for the Neuropathic Pain Market 66

4.2.9 Drivers 67

4.2.10 Restraints 67

4.3 Pain Management Therapeutics Market for Migraine 68

4.3.1 Introduction 68

4.3.2 Revenue 68

4.3.3 Branded Vs Generic Share 69


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22

Related medicine technology :

1. Philips Introduces Veradius Neo Mobile C-arm With Flat Detector to Enhance Management of Challenging Patients and Procedures
2. Denali Concrete Management Inc. Announces its Acquisition of CF101 for Ophthalmic Indications and the Completion of Above $6 Million Private Placement at $1.144 Per Share
3. KJAYA Medical Honored with 2011 Frost & Sullivan Award for Technology Innovation in Web-based Medical Imaging Data Management
4. MedVantx Launches Patient Profile™, A Proprietary Closed-Loop Pharmaceutical Adherence Management Program for Medical Home, Accountable Care and Population Health Management
5. Ultragenyx Appoints Tom Kassberg as Chief Business Officer and Announces Management Team
6. Prime Therapeutics Launches Retail Medication Therapy Management Program
7. MedBox Medication Dispensing: Reducing Preventable ER Trips Through Better Medication Management
8. Orthofeet Expands Sales and Operations Management
9. NxStage Awarded Multi-Year Contract to Supply Atlantic Dialysis Management Services with Vasc-Alert Access Surveillance Solution
10. Sleep HealthCenters Launches PAPCenter™ PAP Therapy Compliance Management Program
11. Rapid Fire Marketing: Medical Cannabis Management Signs Agreement with Second Non-Profit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... N.J., Feb. 27, 2015  PTC Therapeutics, Inc. (NASDAQ: ... and reported financial results for the fourth quarter and ... "2014 was a transformative year for PTC. We are ... and developing RNA-targeted therapies in the rare disease space," ... Therapeutics, Inc. "We are proud to bring the first ...
(Date:2/27/2015)...  Bionik Laboratories Corp. (OTC:DWTPD), a Delaware ... acquired Bionik Laboratories, Inc., a Toronto ... qualified accredited investors of units consisting of its common ... $6.2 million. Shares of the Company,s common stock will ... the symbol "DWTPD" until FINRA,s approval of the ticker ...
(Date:2/26/2015)... , February 27, 2015 ... H2 2014 market research report to its store. ... Corneal Ulcers, therapeutic pipeline. The report ... on the therapeutic development for Corneal Ulcers. Corneal ... that includes bacterial infections, viral infections & fungal ...
Breaking Medicine Technology:PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 2PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 3PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 4PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 5PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 6PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 7PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 8PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 9PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 10PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 11Bionik Laboratories Raises $6.2 Million 2Bionik Laboratories Raises $6.2 Million 3Corneal Ulcers Therapeutics Companies and Drugs Pipeline H2 2014 Review Research Report 2Corneal Ulcers Therapeutics Companies and Drugs Pipeline H2 2014 Review Research Report 3Corneal Ulcers Therapeutics Companies and Drugs Pipeline H2 2014 Review Research Report 4Corneal Ulcers Therapeutics Companies and Drugs Pipeline H2 2014 Review Research Report 5
... , April 29 Abraxis BioScience initially ... the former ICN/Valient Pharmaceutical building in Costa Mesa, ... foot building. The "due diligence report" revealed an array ... occupying the building, and once the building purchase was ...
... April 29 Dendreon Corporation (Nasdaq: ... Food and Drug Administration (FDA) has approved PROVENGE® ... of asymptomatic or minimally symptomatic metastatic, castrate-resistant (hormone-refractory) ... an immune response against prostatic acid phosphatase (PAP), ...
Cached Medicine Technology:LCS Constructors, Inc. Completes First Major Phase of Abraxis BioScience Project 2FDA Approves PROVENGE(R) for the Treatment of Men with Advanced Prostate Cancer 2FDA Approves PROVENGE(R) for the Treatment of Men with Advanced Prostate Cancer 3FDA Approves PROVENGE(R) for the Treatment of Men with Advanced Prostate Cancer 4FDA Approves PROVENGE(R) for the Treatment of Men with Advanced Prostate Cancer 5FDA Approves PROVENGE(R) for the Treatment of Men with Advanced Prostate Cancer 6FDA Approves PROVENGE(R) for the Treatment of Men with Advanced Prostate Cancer 7
(Date:3/1/2015)... Michigan (PRWEB) March 01, 2015 Women’s ... to treat Overactive Bladder (OAB) symptoms, such as a strong ... when another type of medication (anticholinergic) does not work well ... treatment option that takes another approach to targeting the source ... works on the nerves and bladder muscle, blocking the signals ...
(Date:3/1/2015)... (PRWEB) March 01, 2015 Researchers say ... that so many sheet metal workers contract malignant mesothelioma. ... new report on its website. Click here to ... for Construction Research and Training monitored 17,345 sheet metal ... disproportionate number of them died of mesothelioma or ...
(Date:3/1/2015)... The number of transvaginal mesh lawsuits ( ... weeks in two New Jersey litigations where attorneys at ... announces. , A Case List updated on February ... proceeding established for products manufactured by Johnson & Johnson's ... when 90 fewer cases had been centralized. Additionally, 1,700 ...
(Date:3/1/2015)... “ The Barrel Mill ” was featured on NewsWatch as ... at the latest and coolest technology products and services available ... technology expert, conducted the review and shared with viewers how ... to Home Distillation of Alcohol, it's understood that oak is ... cool product that’ll help anyone achieve a barrel aged alcohol ...
(Date:2/28/2015)... (PRWEB) February 28, 2015 The MCA ... across Malaysia into one platform and gears towards the ... , A series of group talks in smaller groups ... Nation Building, Education, Personal Development, Leadership, Entrepreneurship, Healthcare, Social ... raise awareness of Malaysian youths. , Young ...
Breaking Medicine News(10 mins):Health News:Women's Excellence Now Offers BOTOX For Overactive Bladder Treatment 2Health News:New Study Finds Indirect Asbestos Exposure Can Raise Mesothelioma Risk for Sheet Metal Workers, According to Surviving Mesothelioma 2Health News:Bernstein Liebhard LLP Comments on Case List Growth in New Jersey Transvaginal Mesh Litigations, Where Firm Attorneys are Representing Hundreds 2Health News:Bernstein Liebhard LLP Comments on Case List Growth in New Jersey Transvaginal Mesh Litigations, Where Firm Attorneys are Representing Hundreds 3Health News:Bernstein Liebhard LLP Comments on Case List Growth in New Jersey Transvaginal Mesh Litigations, Where Firm Attorneys are Representing Hundreds 4Health News:An Oak Infusion Spiral was Featured on NewsWatch Television on January 30, 2015 2Health News:My Mobile University Appointed Learning Partner for the Upcoming MCA’S First Youth Empowerment Conference Held in Malaysia on March 28, 2015 2Health News:My Mobile University Appointed Learning Partner for the Upcoming MCA’S First Youth Empowerment Conference Held in Malaysia on March 28, 2015 3Health News:My Mobile University Appointed Learning Partner for the Upcoming MCA’S First Youth Empowerment Conference Held in Malaysia on March 28, 2015 4
... (Nasdaq: ANSV ) today announced that that John ... the following events in,November: Rodman & Renshaw 9th ... p.m. ET Presentation: http://www.wsw.com/webcast/rrshq12/ansv , 19th ... 4:30 p.m. ET Presentation: http://www.piperjaffray.com/conferences , ...
... Near-term Pipeline of Products Designed to Deter ... Common Methods of ... ,King Pharmaceuticals, Inc. (NYSE: KG ) and Acura Pharmaceuticals, ... entered into,a License, Development and Commercialization Agreement (the "Agreement"),for the ...
... New business awards a record $175 million; net book-to-bill of 1.7:1, - Total business ... margin of 14.2% (GAAP) and 15.3% (proforma) ... revenues of $100.1 million, up 33% over third quarter ... ...
... StemCor Systems, Inc., a,medical device company developing ... it has received 510(k) clearance from,the U.S. ... its MarrowMiner(TM),for the harvest of bone marrow. ... clearance of StemCor,s MarrowMiner is a major,accomplishment ...
... Oct. 30 Barack Obama today,stepped ahead of all ... areas of foreign policy, the effort to eradicate extreme ... area, he pledged to,increase spending on global HIV/AIDS to ... time increasing overall foreign assistance spending to,$50 billion annually. ...
... $45 Million Reflecting 79% Growth Over Prior Year Quarter; ... Guidance and Reaffirms 2008 Guidance, COEUR D,ALENE, Idaho, ... ), the leading provider of radiology,solutions to radiology groups ... third quarter ended September 30, 2007. Revenue,grew 79% year-over-year ...
Cached Medicine News:Health News:Anesiva Announces Upcoming Webcasts and Conference Participation 2Health News:King Pharmaceuticals and Acura Pharmaceuticals Enter Agreement to Develop and Commercialize Immediate Release Pain Medicines Utilizing Acura's Aversion(R) (Abuse-Deterrent) Technology 2Health News:King Pharmaceuticals and Acura Pharmaceuticals Enter Agreement to Develop and Commercialize Immediate Release Pain Medicines Utilizing Acura's Aversion(R) (Abuse-Deterrent) Technology 3Health News:King Pharmaceuticals and Acura Pharmaceuticals Enter Agreement to Develop and Commercialize Immediate Release Pain Medicines Utilizing Acura's Aversion(R) (Abuse-Deterrent) Technology 4Health News:King Pharmaceuticals and Acura Pharmaceuticals Enter Agreement to Develop and Commercialize Immediate Release Pain Medicines Utilizing Acura's Aversion(R) (Abuse-Deterrent) Technology 5Health News:King Pharmaceuticals and Acura Pharmaceuticals Enter Agreement to Develop and Commercialize Immediate Release Pain Medicines Utilizing Acura's Aversion(R) (Abuse-Deterrent) Technology 6Health News:Kendle Delivers Record Sales and Backlog and Strong Growth in Operating Margin for Third Quarter 2007 2Health News:Kendle Delivers Record Sales and Backlog and Strong Growth in Operating Margin for Third Quarter 2007 3Health News:Kendle Delivers Record Sales and Backlog and Strong Growth in Operating Margin for Third Quarter 2007 4Health News:Kendle Delivers Record Sales and Backlog and Strong Growth in Operating Margin for Third Quarter 2007 5Health News:Kendle Delivers Record Sales and Backlog and Strong Growth in Operating Margin for Third Quarter 2007 6Health News:Kendle Delivers Record Sales and Backlog and Strong Growth in Operating Margin for Third Quarter 2007 7Health News:Kendle Delivers Record Sales and Backlog and Strong Growth in Operating Margin for Third Quarter 2007 8Health News:Kendle Delivers Record Sales and Backlog and Strong Growth in Operating Margin for Third Quarter 2007 9Health News:StemCor Systems Receives FDA Clearance for Bone Marrow Harvesting System 2Health News:StemCor Systems Receives FDA Clearance for Bone Marrow Harvesting System 3Health News:Obama Pledges Major Expansion of AIDS and Global Poverty Programs 2Health News:NightHawk Radiology Holdings, Inc. Releases Record Third Quarter 2007 Results 2Health News:NightHawk Radiology Holdings, Inc. Releases Record Third Quarter 2007 Results 3Health News:NightHawk Radiology Holdings, Inc. Releases Record Third Quarter 2007 Results 4Health News:NightHawk Radiology Holdings, Inc. Releases Record Third Quarter 2007 Results 5Health News:NightHawk Radiology Holdings, Inc. Releases Record Third Quarter 2007 Results 6Health News:NightHawk Radiology Holdings, Inc. Releases Record Third Quarter 2007 Results 7Health News:NightHawk Radiology Holdings, Inc. Releases Record Third Quarter 2007 Results 8Health News:NightHawk Radiology Holdings, Inc. Releases Record Third Quarter 2007 Results 9Health News:NightHawk Radiology Holdings, Inc. Releases Record Third Quarter 2007 Results 10Health News:NightHawk Radiology Holdings, Inc. Releases Record Third Quarter 2007 Results 11Health News:NightHawk Radiology Holdings, Inc. Releases Record Third Quarter 2007 Results 12Health News:NightHawk Radiology Holdings, Inc. Releases Record Third Quarter 2007 Results 13Health News:NightHawk Radiology Holdings, Inc. Releases Record Third Quarter 2007 Results 14Health News:NightHawk Radiology Holdings, Inc. Releases Record Third Quarter 2007 Results 15Health News:NightHawk Radiology Holdings, Inc. Releases Record Third Quarter 2007 Results 16
Performa cemented stem....
Porous foundation 480 series....
Porous foundation 440 series....
A cementless femoral stem that promotes bone in-growth and reduces thigh pain....
Medicine Products: